NASDAQ · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · SMALL CAP
Virax Biolabs Group Ltd. VRAX
5 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$6,331
▼ 96.0% vs FY2023
EPS · FY24
$-1.62
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-109.6%
Net margin · FY24
-95739.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 6,331.00
Revenue, FY2024 · full 5-year series below
Revenue
Net income
The company lost 95739 cents on every revenue dollar this year.
Per share
USD -1.62
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-109.6%
Return on equity, FY2024
ROE
Operating margin-97344.8%
Net margin-95739.2%
Return on assets-101.8%
Each USD of equity lost 110 cents this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 6.4M
total assets, end of FY2024
Total assetsUSD 6.4M
EquityUSD 5.7M
CashUSD 4.2M
Current ratio7.27×
Equity funds 89% of total assets.
History
5 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
Revenue $B
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
·
·
·
Income tax $B
−0.0
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.62
−3.36
−5.13
−1.79
·
Dividend / sh $
·
·
·
·
·
Payout %
·
·
·
·
·
ROE %
−109.6
−92.9
−133.9
·
·
Shares out B
0.00
0.00
0.00
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
18 of 18
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed